The Tiny Biotech That Just Embarrassed AbbVie's Dermatology Team

On the surface, AbbVie's gap looks better. But Avalo's absolute response rate (the raw percentage of patients who improved) was higher: 42-43% versus 38.5%. That matters because in the real world, patients don't care about statistical adjustments. They care about whether they got better.

Avalo claims these are the "highest absolute HiSCR75 rates" in any HS trial of this size or larger. If that holds up in Phase 3, it's a compelling story for doctors choosing between treatments.

And the dosing schedule adds another advantage. The 300 mg arm used monthly injections (every four weeks), compared to biweekly dosing for the lower dose. Monthly shots are a meaningful convenience win for patients managing a chronic disease.

The Money Tells the Real Story

Within 48 hours of the data drop, Avalo priced a $375 million offering at $17.75 per share (a 9% premium to the May 6 close). That's not a company scrambling for survival funding. That's a company capitalizing on momentum to fully bankroll a registrational program.

The analyst community responded accordingly. BTIG set a $58 price target, implying 256% upside. Wolfe Research came in at $48. Even the consensus of 10 analysts averaged nearly $48, with only one dissenting sell rating.

Retail traders went equally wild. Message volume on Stocktwits surged 5,900% in 24 hours, with sentiment flipping from bearish to "extremely bullish." The stock crossed its 50-day moving average for the first time in a month and hit two-year highs.

The Elephant in the Room: Who Buys Avalo?

A small biotech with strong Phase 2 data in a validated indication, $375 million in fresh cash, and a clear Phase 3 path? That's the textbook profile of an acquisition target.

Post-offering (with dilution from new shares and warrants), the fully diluted value creeps toward $840 million to $1 billion. Analyst price targets imply an enterprise value well above $2 billion on success.

The obvious suitor is AbbVie, which built its empire on Humira (a drug that once generated $21 billion annually, partly from HS). AbbVie is already running its own HS program with lutikizumab, but abdakibart's data arguably looks cleaner on absolute efficacy. Buying Avalo could give AbbVie a belt-and-suspenders approach to the indication, or simply eliminate a competitor.

UCB (with its IL-17 drug Bimzelx already selling in HS) is another logical acquirer. So is any large immunology-focused pharma looking to expand in dermatology.

What Could Go Wrong

The placebo problem doesn't disappear in Phase 3. If anything, larger trials often see higher placebo rates because enrollment criteria loosen. Avalo needs to demonstrate it can manage this headwind consistently.

There's also the competitive reality: AbbVie has nearly unlimited resources, a massive salesforce already calling on dermatologists, and its own Phase 3 program running in parallel. Even if abdakibart wins on data, commercial execution against a giant is a different game entirely.

Safety looks clean so far (no neutropenia or serious infections), but 253 patients over 16 weeks is a small window. Phase 3 will need to confirm that profile over longer periods in larger groups.

The Bottom Line

Avalo just delivered the kind of Phase 2 result that turns a small biotech into a multi-billion-dollar takeout candidate. The data isn't perfect; that placebo rate is a legitimate concern, and cross-trial comparisons are notoriously unreliable. But absolute response rates above 42% in moderate-to-severe HS, with monthly dosing and a clean safety profile, is exactly the kind of package that makes big pharma executives pick up the phone.

The question isn't whether abdakibart works. The Phase 2 answered that. The question is whether Avalo gets to run Phase 3 on its own terms, or whether someone with deeper pockets makes them an offer they can't refuse.

The FDA Just Killed the 60-Year-Old Way We Run Clinical Trials

The FDA is letting Amgen and AstraZeneca stream clinical trial data to regulators in real time, ditching the decades-old "run the study, then submit everything" model. If it works, drug development timelines could compress by months, and the entire industry will want in.